Lisata Therapeutics, Inc.

Welcome to the Lissetta Therapeutics third quarter 2022 financial results and business update conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star one one on your telephone. You will then hear an automated message advising you that your hand is raised. As a reminder, this call is being recorded today, Thursday, November 10th, 2022. I will now turn the call over to John Mendetto, Vice President of Vesta Relations and Corporate Communications at La Seta. Please go ahead, sir.

Thank you, Operator, and good afternoon, everyone. Welcome to Lissata's third quarter 2022 conference call to discuss our financial results and provide a business update. Joining me today from our management team are Dr. David Mazzo, Chief Executive Officer, David Slack, President and Chief Business Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Vice President of Finance and Treasury. Shortly before this call, we issued a press release announcing our third quarter 2022 financial results, which is available under the Investors and News section of the company website, along with the webcast replay of this call. If you have not received the news release or if you'd like to be added to the company's email distribution list, please email me at jmindido at lizata.com. Before we begin, I remind you that comments made by management during this conference call contain forward-looking statements that involve risks and uncertainties regarding the future operations and results of Lizada. I encourage you to review the company's filings with the Securities and Exchange Commission, including without limitation its forms 10Q, 8K, and 10K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as the date of the live broadcast, Thursday, November 10th, 2022. Lizada undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I will now turn the call over to Dr. Mazzo. Dave?

Thank you, John, and good afternoon, everyone. It gives me great pleasure today to host this, our first quarterly conference call as Lasada Therapeutics, where we will provide an overview of recent business highlights and discuss our third quarter 2022 financial results. At Lasada, we strive to create value for our shareholders and for our stakeholders, the patients who suffer from the debilitating and often grave diseases that we have targeted and the physicians who treat them by developing and commercializing products that address important unmet medical needs. Our portfolio of product candidates contains treatments in development that are designed to be regenerative and or to bring significant therapeutic improvement. As a development company, our focus is on the generation of meaningful data by the most expeditious and cost-effective means as evidenced by the fact that even though our merger with SEND Therapeutics occurred approximately six weeks ago, we are in a position today to report tangible progress advancing LSTA-1, or Lista-1 as we call it internally, the company's lead investigational product candidate from our proprietary Sendar platform. Lista-1 is the subject of multiple planned and ongoing clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens. Based on favorable safety, tolerability, and activity data to date, we believe Lister 1 has the potential to become an integral part of a revised standard of care therapy for many difficult-to-treat cancers. In the past few weeks, we have received advice from the U.S. Food and Drug Administration on what would be required of us for registration. We have discussed this guidance with our development partners, and we are now preparing for the implementation of protocol changes that we expect will improve the regulatory standing and scientific value of our studies. Our Chief Medical Officer, Dr. Buck, will provide more specifics on our clinical program shortly following our review of the quarter's financial results. However, before getting into that, allow me to introduce LASADA's President and Chief Business Officer, David Slack. David is a seasoned industry executive with over 25 years of experience in public and private life science companies, working in a variety of senior business roles. We believe that his experience and expertise will prove instrumental to Lazada as we work to expand the applicability of ListaOne and the Sendar platform programs to other solid tumor targets, treatment combinations, and corporate partnerships. With that, I'll turn the call over to David. Oh, and by the way, In order to avoid confusion internally, we've adopted the convention of referring to David as David and to me as Dave. David?